ceftobiprole and Bacteremia

Ceftobiprole is a new cephalosporin with an extended spectrum activity against the majority of microorganisms isolated in bacteremia including methicillin-susceptible (MSSA) and -resistant S. aureus (MRSA). This antibiotic has demonstrated a potent activity against MRSA in animal models of endocarditis in monotherapy but particularly in combination with daptomycin, suggesting that this combination could be a future option to improve the outcome of staphylococcal endovascular infections. In addition, the extended-spectrum ceftobiprole activity, including coagulase-negative staphylococci, Enterococcus faecalis, Enterobacteriaceae and Pseudomonas aeruginosa represents an advantage for use as empirical therapy in bacteremia potentially caused by a broad spectrum of microorganisms, such as in catheter-related bacteremia.

Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Daptomycin; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Pseudomonas aeruginosa; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus

Although

Topics: Adult; Bacteremia; Cephalosporins; Clinical Trials as Topic; Daptomycin; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Female; Hospitalization; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Staphylococcal Infections; Staphylococcus aureus; Treatment Failure; Treatment Outcome; Young Adult

Coagulase-negative staphylococci (CoNS) and especially

Topics: Anti-Bacterial Agents; Bacteremia; Biofilms; Catheters; Daptomycin; Humans; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus epidermidis; Vancomycin

Topics: Animals; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Disease Models, Animal; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus

Ceftobiprole medocaril, the prodrug of ceftobiprole, is an advanced-generation cephalosporin that is approved in many European and non-European countries for the treatment of adults with hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia and is currently being evaluated in a global phase 3 clinical trial of patients with Staphylococcus aureus bacteremia. This study investigated the in vitro activity of ceftobiprole and comparators against a total of 5466 gram-positive and -negative isolates from bloodstream infections (BSIs) that were collected in the United States during 2016 and 2017 as part of the SENTRY Antimicrobial Surveillance Program. Ceftobiprole was highly active (isolates were >99% susceptible) against S. aureus (including methicillin-resistant S. aureus), coagulase-negative staphylococci, Enterococcus faecalis, streptococci, and non-extended-spectrum β-lactamase (non-ESBL) phenotype Enterobacteriaceae. As expected, lower activities were observed against Enterococcus faecium, ESBL-phenotype Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. These results support further clinical evaluation of ceftobiprole for the treatment of BSIs caused by susceptible organisms.

Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; United States

Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Pneumonia, Bacterial; Pseudomonas; Staphylococcal Infections; Staphylococcus aureus

Topics: Anti-Infective Agents; Bacteremia; Cephalosporins; Drug Resistance, Bacterial; Epidemiological Monitoring; Humans; Ireland; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus; United Kingdom